By detecting the expression levels of PD-1 and PD-L1 in the blood of lung cancer patients, the drug treatment regimen of PD-1 and PD-L1 can be formulated based on the test results, and the patients’ response to immunotherapy can be further assessed. This evidence concerns the gene CD274 and lung cancer.